To the Editor: In the Commentary by Drs Psaty and Prentice1 on event rates in 5 trials of glucose lowering, the authors expressed the opinion that the variation in rates of MI among studies cannot be explained by differences in baseline cardiovascular risk factors. Consequently, they advised caution in interpreting results, particularly from the trials with low event rates such as RECORD,2 and further suggested that absolute event rates may be used to assess trial quality.
Preiss D, Sattar N, McMurray JJ. Event Rates in Trials of Patients With Type 2 Diabetes. JAMA. 2010;303(8):732-733. doi:10.1001/jama.2010.138